Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q4 FY22 results · Jan–Mar 2022
Alkem Laboratories reported revenue from operations of ₹2,483.86 crore (up 13.3% from Q4 FY21) and net profit of ₹108.21 crore (down 56.6% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,483.86 | 2,192.16 | +13.3% | 2,618.98 | −5.2% |
| Other income | 20.52 | 46.28 | −55.7% | 53.52 | −61.7% |
| Total income | 2,504.38 | 2,238.44 | +11.9% | 2,672.50 | −6.3% |
| Profit before tax | 242.68 | 258.16 | −6.0% | 463.94 | −47.7% |
| Net profit for the period | 108.21 | 249.22 | −56.6% | 533.35 | −79.7% |
| Attributable to shareholders of the company | 107.58 | 239.99 | −55.2% | 525.66 | −79.5% |
| EPS, basic (₹) | 9.00 | 20.07 | −55.2% | 43.96 | −79.5% |
| Net margin (%) | 4.4 | 11.4 | 20.4 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,006.31 | 1,917.47 | +4.6% | 2,180.84 | −8.0% |
| Other income | 54.23 | 48.77 | +11.2% | 63.24 | −14.2% |
| Total income | 2,060.54 | 1,966.24 | +4.8% | 2,244.08 | −8.2% |
| Profit before tax | 185.83 | 395.66 | −53.0% | 469.81 | −60.4% |
| Net profit for the period | 76.88 | 362.74 | −78.8% | 437.09 | −82.4% |
| EPS, basic (₹) | 6.43 | 30.34 | −78.8% | 36.56 | −82.4% |
| Net margin (%) | 3.8 | 18.9 | 20.0 |
Consolidated
- Filed with BSE
- 14 May 2022, 11:10 IST
- Board meeting
- 13 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 May 2022, 11:10 IST
- Board meeting
- 13 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE